

## **Product** Data Sheet

## **Trabikibart**

**Cat. No.:** HY-P990094 **CAS No.:** 2643974-98-3

Target: Others
Pathway: Others

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## **BIOLOGICAL ACTIVITY**

Description

Trabikibart (CSL311), a  $\beta$ c-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human  $\beta$ c receptor. Trabikibart has picomolar binding affinity for the human  $\beta$ c receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research<sup>[1]</sup>.

## **REFERENCES**

[1]. Con Panousis, et al. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common  $\beta$  chain of the IL-3, GM-CSF and IL-5 receptors. MAbs. 2016;8(3):436-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors • Screening Libraries

ies • Proteins

Page 1 of 1